Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elicio Therapeutics, Inc. (Nasdaq: ELTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Elicio is a clinical-stage biotechnology company developing AMP-based, off-the-shelf immunotherapies for mKRAS-driven and other cancers, and its filings offer detailed insight into this development strategy, financial position, and risk profile.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe Elicio’s clinical programs such as ELI-002 2P and 7P, the AMPLIFY-201 and AMPLIFY-7P trials in pancreatic and colorectal cancers, the broader AMP platform, and the company’s liquidity and operating expenses. Current reports on Form 8-K capture material events, including the release of clinical immunogenicity data, recommendations from the Independent Data Monitoring Committee for the Phase 2 AMPLIFY-7P study, publication of Phase 1 results in peer-reviewed journals, and the announcement of quarterly financial results.
Investors interested in insider activity can also look for Forms 3, 4 and 5, which disclose transactions by directors, officers and significant shareholders, where available. Proxy statements on Schedule 14A may provide information on governance matters and executive compensation related to Elicio’s leadership team and board.
On Stock Titan, Elicio’s SEC filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key sections related to ELI-002, the AMP platform, clinical trial milestones, and cash runway, and help explain complex disclosures in accessible language. This allows users to quickly identify important changes in Elicio’s clinical development plans, financial condition, and risk factors without reading every page of each filing.